{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:55:41Z","timestamp":1790934941316,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.pharma.2010.09.001","type":"journal-article","created":{"date-parts":[[2010,12,25]],"date-time":"2010-12-25T04:18:04Z","timestamp":1293250684000},"page":"7-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u00c9tude des m\u00e9tatrajectoires des taux de CD4\u00a0par taxonomie dans la r\u00e9ponse du r\u00e9gime antir\u00e9troviral \u00e0 base d\u2019\u00e9favirenz chez des patients na\u00effs symptomatiques \u00e0 Abidjan"],"prefix":"10.1016","volume":"69","author":[{"given":"D.P.","family":"Abrogoua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Aulagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Kablan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2010.09.001_bib0005","series-title":"Rapport mondial sur l\u2019\u00e9pid\u00e9mie du sida","author":"Onusida","year":"2007"},{"key":"10.1016\/j.pharma.2010.09.001_bib0010","series-title":"Mod\u00e9lisation longitudinale de marqueurs du VIH [th\u00e8se no\u00a0988]","author":"Thi\u00e9baut","year":"2002"},{"key":"10.1016\/j.pharma.2010.09.001_bib0015","first-page":"106","article-title":"\u00c9tude de la r\u00e9gion de l\u2019amas Virgo par taxonomie","volume":"71","author":"Paturel","year":"1979","journal-title":"Astron Astrophys"},{"key":"10.1016\/j.pharma.2010.09.001_bib0020","series-title":"M\u00e9ta-apprentissage d\u2019exp\u00e9riences\u00a0: une nouvelle voie en data mining","author":"Petit","year":"2005"},{"key":"10.1016\/j.pharma.2010.09.001_bib0025","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study","volume":"363","author":"Eth","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2010.09.001_bib0030","unstructured":"Danel C, Moh R, Messou E, Minga A, et al. Short-term tolerance of efavirenz in HIV-infected african adults participating in the trivacan ANRS 1269\u00a0trial, Abidjan, C\u00f4te d\u2019Ivoire. Abstract 53, 2nd IAS conference on HIV pathogenesis and treatment. Paris, France, 13\u201316July, 2003."},{"key":"10.1016\/j.pharma.2010.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/00002030-200109070-00011","article-title":"Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir or efavirenz","volume":"15","author":"Lucas","year":"2001","journal-title":"AIDS"},{"issue":"Suppl. 3","key":"10.1016\/j.pharma.2010.09.001_bib0040","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1097\/00002030-200317003-00012","article-title":"The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: empirical data from C\u00f4te d\u2019Ivoire's drug access initiative","volume":"17","author":"Diomande","year":"2003","journal-title":"AIDS"},{"issue":"Suppl. 3","key":"10.1016\/j.pharma.2010.09.001_bib0045","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00002030-200317003-00001","article-title":"The evaluation of the HIV\/AIDS drug access initiatives in C\u00f4te d\u2019Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa","volume":"17","author":"Katzenstein","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0050","unstructured":"Organisation mondiale de la sant\u00e9. Traitement antir\u00e9troviral de l\u2019infection \u00e0 VIH chez l\u2019adulte et l\u2019adolescent en situation de ressources limit\u00e9es\u00a0: vers un acc\u00e8s universel. Recommandations pour une approche de sant\u00e9 publique; version 2006. OMS, Gen\u00e8ve WC 503.2;2008."},{"key":"10.1016\/j.pharma.2010.09.001_bib0055","unstructured":"Organisation mondiale de la sant\u00e9. Global Tuberculosis Control 2008: surveillance, planning, financing. Gen\u00e8ve WHO\/HTM\/TB\/2008,393;2008."},{"key":"10.1016\/j.pharma.2010.09.001_bib0060","series-title":"M\u00e9mento th\u00e9rapeutique du VIH\/sida en Afrique","author":"Eholi\u00e9","year":"2005"},{"key":"10.1016\/j.pharma.2010.09.001_bib0065","unstructured":"WHO\/Unicef\/UNO. Iron deficiency indicators: assessment and strategies for prevention. Geneve;1998."},{"key":"10.1016\/j.pharma.2010.09.001_bib0070","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1001\/jama.282.23.2220","article-title":"Opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study","volume":"282","author":"Ledergerber","year":"1999","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pharma.2010.09.001_bib0075","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/00002030-199817000-00013","article-title":"Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d\u2019\u00e9pidemiologie clinique du sida en Aquitaine","volume":"12","author":"Ch\u00eane","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0080","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.medmal.2008.02.004","article-title":"\u00c9favirenz versus indinavir chez les patients na\u00effs infect\u00e9s par le VIH1\u00a0\u00e0 Abidjan (C\u00f4te d\u2019Ivoire)","volume":"38","author":"Tanon","year":"2008","journal-title":"Med Mal Infect"},{"issue":"1","key":"10.1016\/j.pharma.2010.09.001_bib0085","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/01.qai.0000219777.04927.50","article-title":"Tolerance and acceptability of an efavirenz-based regimen in 740\u00a0adults (predominantly women) in West Africa","volume":"42","author":"Danel","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.pharma.2010.09.001_bib0090","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00002030-200104130-00009","article-title":"Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study","volume":"15","author":"Yamashita","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0095","first-page":"195","article-title":"An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996\u00a0through 2002","volume":"39","author":"Moore","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.pharma.2010.09.001_bib0100","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/00126334-200406010-00007","article-title":"Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count","volume":"36","author":"Garcia","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.pharma.2010.09.001_bib0105","doi-asserted-by":"crossref","unstructured":"Moore D, Hogg R, Yip B, et al. Baseline CD4\u00a0percentage is predictive of survival in patients starting antiretroviral therapy, including those with CD4\u00a0cell counts between 200\u00a0and 350cells\/mL. 12th CROI, Boston;2005 [abstract 589]","DOI":"10.1111\/j.1468-1293.2006.00397.x"},{"key":"10.1016\/j.pharma.2010.09.001_bib0110","unstructured":"Agence nationale de recherche sur le sida. L\u2019observance aux traitements contre le VIH\/sida: mesure, d\u00e9terminants, \u00e9volution. Collection sciences sociales et sida, France;2001."},{"key":"10.1016\/j.pharma.2010.09.001_bib0115","unstructured":"Eholi\u00e9 SP. Analyse de l\u2019observance au traitement antir\u00e9troviral \u00e0 Abidjan abstract (971451), 13th ICASA 22\u201325septembre2003."},{"key":"10.1016\/j.pharma.2010.09.001_bib0120","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/00002030-200306130-00011","article-title":"Adherence is not a barrier to successful antiretroviral therapy in South Africa","volume":"17","author":"Orrel","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0125","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/00002030-200309050-00023","article-title":"M\u00e9decins sans fronti\u00e8res. Highly active antiretroviral therapy in resource-poor settings: the experience of M\u00e9decins sans fronti\u00e8res","volume":"17","author":"Tassie","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0130","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1097\/00002030-200317003-00014","article-title":"Adherence to HAART and it principal determinants in a cohort of Senegalese adults","volume":"17","author":"Lani\u00e8ce","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0135","first-page":"1053","article-title":"Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa","volume":"20","author":"Nachega","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0140","unstructured":"Daniel OJ, Ogun SA, Odusoga OL, Falola RL, Ogundahunsi OA, Salako AA, et al. Adherence pattern to ARV drugs among AIDS patients on sef-purcased drugs and those on free medications in Sagamu, Nigeria. XV International AIDS Conference. Bangkok, March30\u2013April2, 2004."},{"key":"10.1016\/j.pharma.2010.09.001_bib0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/QAI.0b013e31805d8ad0","article-title":"Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, C\u00f4te d\u2019Ivoire","volume":"45","author":"Eholi\u00e9","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.pharma.2010.09.001_bib0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00126334-200404010-00008","article-title":"Total lymphocyte count, haemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy","volume":"35","author":"Anastos","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"10.1016\/j.pharma.2010.09.001_bib0155","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ije\/dyi023","article-title":"HIV-1\u00a0subtype E progression among northern Thai couples: traditional and nontraditional predictors of survival","volume":"34","author":"Costello","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.pharma.2010.09.001_bib0160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00002030-199905280-00010","article-title":"Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe","volume":"13","author":"Morcroft","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.pharma.2010.09.001_bib0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00042560-199809010-00004","article-title":"Anemia and survival in HIV infection","volume":"19","author":"Moore","year":"1998","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"10.1016\/j.pharma.2010.09.001_bib0170","first-page":"302","article-title":"Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project","volume":"1","author":"Sullivan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2010.09.001_bib0175","series-title":"Prise en charge des personnes infect\u00e9es par le VIH\u00a0: recommandations du groupe d\u2019experts","author":"Yeni","year":"2008"},{"key":"10.1016\/j.pharma.2010.09.001_bib0180","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00126334-200106010-00012","article-title":"Increase and plateau of CD4\u00a0T-cell counts in the 3\u20131\/2\u2013years after initiation of potent antiretroviral therapy","volume":"27","author":"Tarwater","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"10.1016\/j.pharma.2010.09.001_bib0185","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/aje\/kwi268","article-title":"Individual variation in CD4\u00a0cell count trajectory among human immunodeficiency virus-infected men and women on long-term highly active antiretroviral therapy: an application using a Bayesian random change-point model","volume":"162","author":"Chu","year":"2005","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pharma.2010.09.001_bib0190","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1097\/00002030-200207260-00014","article-title":"High effectiveness of efavirenz based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100\u00a0CD4\u00a0cells\/microliter and opportunistic diseases: the Efa-VIP Study (Efavirenz in very immunosuppressed patients)","volume":"16","author":"Arribas","year":"2002","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.pharma.2010.09.001_bib0195","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00126334-200404010-00003","article-title":"Clinical, virologic, and immunologic response to efavirenz or protease inhibitor\u00a0\u2013\u00a0based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2\u00a0Study)","volume":"35","author":"Pulido","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.pharma.2010.09.001_bib0200","unstructured":"Petit C. Nouvelle technique d\u2019analyse et pr\u00e9diction en urgence\u00a0: les m\u00e9tatrajectoires (abstract page 8). Congr\u00e8s international interdisciplinaire sur les urgences, CIIU 26\u201330juin2005; Montr\u00e9al, Canada;1045."},{"key":"10.1016\/j.pharma.2010.09.001_bib0205","unstructured":"Prost S, Petit C. Meta-trajectories: a new approach of data mining. ICEIS 2003. Angers, France."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450910001410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450910001410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:28:28Z","timestamp":1757719708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450910001410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0003450910001410"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2010.09.001","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9tude des m\u00e9tatrajectoires des taux de CD4\u00a0par taxonomie dans la r\u00e9ponse du r\u00e9gime antir\u00e9troviral \u00e0 base d\u2019\u00e9favirenz chez des patients na\u00effs symptomatiques \u00e0 Abidjan","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2010.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}